类炼对轻度和中度阿尔茨海默氏症的影响:随机对照试验协议
Rihab Moncer1,2, Habib Hajji1,2, Salma Naija2,3
1Physical and rehabilitation department, Sahloul Hospital of Sousse, Tunisia.
La Tunisie medicale
|January 15, 2025
概括
这项研究调查了阿尔茨海默病 (AD) 患者的类干预. 温和的练习旨在改善认知功能和心理健康,为残疾人提供另一种选择.
科学领域:
- 老年学是指老年学的学科.
- 神经科学是一个神经科学.
- 康复医学 康复医学 康复医学
背景情况:
- 有氧运动有助于认知健康,但对于多重残疾人来说并不总是可行的.
- 对于认知障碍,正在探索柔和的,正念的练习,如类方法.
- 在阿尔茨海默病中,类干预措施的疗效的证据有限.
研究的目的:
- 评估类干预对轻度至中度阿尔茨海默病 (AD) 的认知和心理方面的有效性.
主要方法:
- 一个随机对照试验将将类干预组 (IG) 与对照组 (CG) 进行比较.
- 导师将每周进行30分钟的呼吸,姿势,集中和冥想,每周进行三次,持续八周.
- 神经心理测试评估注意力,解决问题的能力,视觉空间能力,情绪和神经心理症状将在基线和干预后进行.
主要成果:
- 从呼吸,集中力和冥想组件的注意力,问题解决和行为症状的预期改善.
- 对视觉空间控制和平衡的预期改善,归因于干预的姿势元素.
结论:
- 这种类似于的干预措施在改善轻度至中度阿尔茨海默氏症患者的认知和心理特征方面表现有前途.
- 这种方法可能为患有阿尔茨海默症和多重残疾的人提供一种可行和有益的空气运动替代方案.
相关概念视频
Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35


